In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012

In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012–15

Published:2018-07-11 Issue:10 Volume:73 Page:2777-2781
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Kazmierczak Krystyna M¹,de Jonge Boudewijn L M²,Stone Gregory G²,Sahm Daniel F¹

Affiliation:

1. International Health Management Associates, Inc., Schaumburg, IL, USA

2. AstraZeneca Pharmaceuticals, Waltham, MA, USA

Funder

AstraZeneca Pharmaceuticals

International Network for Optimal Resistance Monitoring

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

http://academic.oup.com/jac/article-pdf/73/10/2777/25770325/dky267.pdf

Reference19 articles.

1. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?;Livermore;Clin Infect Dis,2002

2. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms;Lister;Clin Microbiol Rev,2009

3. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa;Rodriguez-Martinez;Antimicrob Agents Chemother,2009

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye;European Journal of Clinical Microbiology & Infectious Diseases;2024-07-12

2. Evolving resistance landscape in gram‐negative pathogens: An update on β‐lactam and β‐lactam‐inhibitor treatment combinations for carbapenem‐resistant organisms;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07

3. Ceftazidime/avibactam resistance is associated with PER-3-producing ST309 lineage in Chilean clinical isolates of non-carbapenemase producing Pseudomonas aeruginosa;Frontiers in Cellular and Infection Microbiology;2024-06-05

4. Prevalence and molecular characteristics of ceftazidime-avibactam resistance among carbapenem-resistant Pseudomonas aeruginosa clinical isolates;Journal of Global Antimicrobial Resistance;2024-03

5. In-vitro Susceptibility Testing Methods for Ceftazidime-avibactam against Carbapenem-resistant Enterobacterales: Comparison with Reference Broth Microdilution Method;Current Drug Safety;2023-11